Peter Malfertheiner Selected Research

Inflammatory Bowel Diseases (Inflammatory Bowel Disease)

12/2019	Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons.
6/2018	Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study.
1/2018	Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases.
4/2011	Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
5/2008	Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors.
4/2005	Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease.
10/2004	Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease.
7/2002	Characterization of novel anti-cathepsin W antibodies and cellular distribution of cathepsin W in the gastrointestinal tract.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Malfertheiner Research Topics

Disease

72	Neoplasms (Cancer) 09/2022 - 01/2002
59	Stomach Neoplasms (Stomach Cancer) 01/2022 - 01/2002
52	Infections 01/2021 - 07/2002
36	Gastroesophageal Reflux (GERD) 12/2018 - 01/2004
31	Hepatocellular Carcinoma (Hepatoma) 09/2022 - 01/2006
24	Carcinogenesis 10/2021 - 01/2002
22	Gastritis 10/2021 - 07/2002
15	Adenocarcinoma 01/2022 - 01/2003
15	Inflammation (Inflammations) 10/2021 - 04/2005
13	Peptic Ulcer (Peptic Ulcers) 01/2021 - 01/2002
13	Ulcer 08/2020 - 01/2002
12	Atrophic Gastritis 01/2021 - 10/2005
12	Dyspepsia (Indigestion) 01/2021 - 01/2003
10	Metaplasia 01/2022 - 05/2002
10	Neoplasm Metastasis (Metastasis) 12/2020 - 05/2003
10	Hemorrhage 09/2016 - 01/2002
9	Pancreatic Neoplasms (Pancreatic Cancer) 02/2020 - 01/2003
9	Atrophy 12/2017 - 05/2002
8	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 12/2019 - 07/2002
8	Pathologic Constriction (Stenosis) 01/2016 - 01/2002
8	Heartburn (Pyrosis) 06/2011 - 07/2006
7	Liver Cirrhosis (Hepatic Cirrhosis) 06/2021 - 01/2009
7	Carcinoma (Carcinomatosis) 09/2011 - 08/2002
6	Liver Neoplasms (Liver Cancer) 04/2022 - 01/2006
6	Diarrhea 09/2021 - 11/2009
6	Chronic Pancreatitis 06/2014 - 01/2002
6	Pancreatitis 03/2014 - 04/2002
5	Fibrosis (Cirrhosis) 12/2021 - 09/2002
5	Colorectal Neoplasms (Colorectal Cancer) 09/2021 - 01/2005
5	Crohn Disease (Crohn's Disease) 08/2012 - 07/2002
4	Ascites 01/2022 - 01/2004
4	Liver Diseases (Liver Disease) 06/2021 - 01/2008
4	Hepatic Encephalopathy 01/2019 - 07/2014
4	Esophagitis 12/2018 - 12/2007
4	Chronic Hepatitis C 11/2017 - 07/2005
4	Disease Progression 02/2016 - 02/2003
4	Weight Loss (Weight Reduction) 03/2014 - 01/2009
4	Ulcerative Colitis 08/2012 - 04/2005
4	Colitis 08/2012 - 10/2004
4	Pain (Aches) 05/2006 - 01/2003
3	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 12/2021 - 02/2006
3	Barrett Esophagus (Barrett's Esophagus) 02/2018 - 01/2008
3	Hyperplasia 12/2017 - 09/2010
3	Colonic Neoplasms (Colon Cancer) 09/2014 - 01/2005

Drug/Important Bio-Agent (IBA)

28	Proteins (Proteins, Gene)FDA Link 10/2018 - 01/2002
21	Biomarkers (Surrogate Marker)IBA 09/2022 - 09/2002
20	AcidsIBA 03/2021 - 05/2006
17	Proton Pump InhibitorsIBA 01/2021 - 01/2003
16	Sorafenib (BAY 43-9006)FDA Link 09/2022 - 01/2011
13	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2012
11	Anti-Bacterial Agents (Antibiotics)IBA 09/2021 - 01/2003
11	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021 - 01/2002
10	Messenger RNA (mRNA)IBA 07/2017 - 01/2002
9	Interleukin-8 (Interleukin 8)IBA 06/2021 - 05/2004
9	EnzymesIBA 02/2015 - 04/2005
8	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 01/2002
8	CytokinesIBA 01/2018 - 04/2005
7	Pepsinogen A (Pepsinogen)IBA 12/2019 - 01/2011
6	AntibodiesIBA 12/2021 - 02/2006
6	Pharmaceutical PreparationsIBA 01/2021 - 10/2005
6	AntigensIBA 10/2018 - 09/2008
6	AntralIBA 01/2011 - 04/2004
5	SirtuinsIBA 09/2022 - 12/2020
5	BilirubinIBA 01/2022 - 06/2014
5	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 12/2005
5	Esomeprazole (Nexium)FDA Link 01/2013 - 12/2005
5	ProteomeIBA 09/2006 - 09/2004
4	AlbuminsIBA 01/2022 - 01/2003
4	Biological ProductsIBA 10/2021 - 01/2007
4	Metronidazole (Metric)FDA LinkGeneric 01/2021 - 04/2004
4	Urea (Carbamide)FDA LinkGeneric 01/2021 - 01/2003
4	Gemcitabine FDA Link 02/2020 - 02/2006
4	Cytotoxins (Cytolysins)IBA 10/2018 - 09/2008
4	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 09/2010
4	Blood Proteins (Serum Proteins)IBA 12/2017 - 11/2004
4	UreaseIBA 10/2011 - 10/2006
4	Secretory Leukocyte Peptidase InhibitorIBA 02/2009 - 04/2004
3	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 04/2010
3	Capsules (Microcapsules)IBA 01/2022 - 03/2011
3	BismuthIBA 01/2021 - 10/2010
3	VaccinesIBA 10/2018 - 09/2008
3	RamucirumabIBA 01/2018 - 01/2017
3	Virulence Factors (Pathogenicity Factors)IBA 12/2014 - 01/2011
3	Transcription Factors (Transcription Factor)IBA 01/2014 - 06/2005
3	AutoantibodiesIBA 01/2013 - 04/2011
3	Clarithromycin (Biaxin)FDA LinkGeneric 01/2013 - 01/2009
3	Cathepsin WIBA 12/2011 - 07/2002
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 08/2011 - 04/2005
3	Omeprazole (Prilosec)FDA LinkGeneric 03/2011 - 01/2003

Therapy/Procedure

77	Therapeutics 05/2022 - 01/2002
9	Drug Therapy (Chemotherapy) 01/2018 - 01/2003
8	Radiotherapy 01/2022 - 01/2003
7	Stents 01/2016 - 11/2003
6	Secondary Prevention 10/2021 - 01/2002
4	Aftercare (After-Treatment) 12/2021 - 08/2005
4	Brachytherapy 02/2019 - 01/2009
4	Gastrectomy 05/2016 - 04/2005
3	Microspheres (Microsphere) 12/2020 - 01/2009
3	Chemoprevention 01/2019 - 09/2005
3	Self Expandable Metallic Stents 01/2016 - 01/2002